India’s separation of medicine licensing under CDSCO and pricing under NPPA presents a policy challenge. Stronger coordination,supported by pharmaceutical, clinical and health-economic expertise, could bridge this gap. Explores how India prices medicines, the gaps between costs and patient prices, and calls for coordinated, evidence-based pricing reform.